Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Kathryn Wisser

Internal Medicine Flint, MI Doctor of Osteopathy

NPI 1073545273 CMS profile 184377

4255 Beecher Rd, Flint, MI 48532

Open in the dashboard

General payments

$5,859

285 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Kathryn Wisser of Flint, MI is reported in the CMS Open Payments database as having received $5,859 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,111 48
2023 General $974 48
2022 General $1,159 61
2021 General $993 49
2020 General $511 17
2019 General $1,111 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathryn Wisser
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kathryn Wisser were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kathryn Wisser Internal Medicine median Middle half National median
2019 $1,111 $159 $48–$570 $163
2020 $511 $119 $33–$402 $114
2021 $993 $135 $37–$521 $132
2022 $1,159 $141 $42–$496 $149
2023 $974 $149 $45–$519 $160
2024 $1,111 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $2,193 125 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,038 44 payments
  3. Gilead Sciences, Inc. $523 28 payments
  4. Janssen Biotech, Inc. $417 22 payments
  5. Allergan Inc. $224 2 payments
  6. Boston Scientific Corporation $130 1 payment
  7. Celgene Corporation $127 8 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $125 1 payment
  9. Regeneron Healthcare Solutions, Inc. $117 5 payments
  10. Intercept Pharmaceuticals, Inc. $106 6 payments
  11. Other $859 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,579 283 payments
  2. Education $218 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $63 1 payment
Products named General payments · program years 2019–2024
  1. HUMIRA $1,056 56 payments
  2. ENTYVIO $811 32 payments
  3. SKYRIZI $414 25 payments
  4. RINVOQ $410 28 payments
  5. STELARA $395 21 payments
  6. MAVYRET $328 19 payments
  7. SIMPONI ARIA $191 10 payments
  8. REMICADE $191 10 payments
  9. SIMPONI $191 10 payments
  10. CREON $153 10 payments
  11. Other $1,946 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

165

Median for Gastroenterology: 569

Drug cost

$930,302

Median for Gastroenterology: $104,976

Branded share of claims

39.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gattex Teduglutide Brand 12 $537,605
Stelara Ustekinumab Brand 12 $332,718
Creon Lipase/Protease/Amylase Brand 17 $39,023
Linzess Linaclotide Brand 13 $10,303
Mesalamine Generic 19 $7,312
Omeprazole Generic 45 $1,121
Sucralfate Generic 11 $877
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 11 $862
Pantoprazole Sodium Generic 25 $482

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$51,639

Medicare's payments for the services billed

Medicare patients

273

Average age 72

Services billed

455

168 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 45%
Depression 22%
Ischemic heart disease 21%
Chronic kidney disease 21%
Cancer 21%
Diabetes 20%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $201
$201 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $67
  • GENZYME CORPORATION $49
$116 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $96
$96 — —
SKYRIZI
  • AbbVie, Inc. $94
$94 — —
RINVOQ
  • AbbVie, Inc. $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record